Sign In
Buy AZYO
$1.49
+0 (+0%)
At Close: Dec 05, 2023
Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:30am, Friday, 08'th Sep 2023
SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
08:30am, Wednesday, 30'th Aug 2023
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket
Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript
12:41pm, Sunday, 20'th Aug 2023
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
04:05pm, Monday, 14'th Aug 2023
Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Card
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
04:05pm, Monday, 31'st Jul 2023
SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products
04:30pm, Thursday, 13'th Jul 2023
SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical device
Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript
09:32pm, Sunday, 14'th May 2023
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Randy Mills - Chief Executive Officer Matt Fergus
Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
04:05pm, Wednesday, 03'rd May 2023
SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between m
Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
11:26am, Wednesday, 05'th Apr 2023
Aziyo Biologics, Inc. (AZYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen
Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript
06:12pm, Wednesday, 22'nd Mar 2023
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Of
ACER's Stock Down on Failure of Phase II Study, Cash Updates
01:46pm, Monday, 20'th Mar 2023
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023
04:05pm, Wednesday, 15'th Mar 2023
SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between
Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference
08:15am, Monday, 27'th Feb 2023
SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between
Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know
01:33pm, Thursday, 26'th Jan 2023
Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aziyo Biologics to Participate in Upcoming Investor Conferences
04:05pm, Monday, 21'st Nov 2022
SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medic
